Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

419 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe.
Cantón R, Akóva M, Carmeli Y, Giske CG, Glupczynski Y, Gniadkowski M, Livermore DM, Miriagou V, Naas T, Rossolini GM, Samuelsen Ø, Seifert H, Woodford N, Nordmann P; European Network on Carbapenemases. Cantón R, et al. Among authors: carmeli y. Clin Microbiol Infect. 2012 May;18(5):413-31. doi: 10.1111/j.1469-0691.2012.03821.x. Clin Microbiol Infect. 2012. PMID: 22507109 Free article. Review.
Expert consensus on antimicrobial resistance research priorities to focus development and implementation of antibacterial vaccines and monoclonal antibodies.
Hassoun-Kheir N, Guedes M, Arieti F, Pezzani MD, Gladstone BP, Robotham JV, Pouwels KB, Kingston R, Carmeli Y, Cassini A, Cecchini M, Drobniewski F, Frost I, Geurtsen J, Kronenberg A, Htay MNN, Paul M, Rocha-Pereira N, Rodríguez-Baño J, Scudeller L, Stewardson AJ, Tacconelli E, Harbarth S, Vella V, de Kraker ME. Hassoun-Kheir N, et al. Among authors: carmeli y. Euro Surveill. 2024 Nov;29(47):2400212. doi: 10.2807/1560-7917.ES.2024.29.47.2400212. Euro Surveill. 2024. PMID: 39574390 Free PMC article.
Aztreonam-avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trial.
Carmeli Y, Cisneros JM, Paul M, Daikos GL, Wang M, Torre-Cisneros J, Singer G, Titov I, Gumenchuk I, Zhao Y, Jiménez-Rodríguez RM, Liang L, Chen G, Pyptiuk O, Aksoy F, Rogers H, Wible M, Arhin FF, Luckey A, Leaney JL, Pypstra R, Chow JW; COMBACTE-CARE consortium REVISIT study group. Carmeli Y, et al. Lancet Infect Dis. 2024 Oct 7:S1473-3099(24)00499-7. doi: 10.1016/S1473-3099(24)00499-7. Online ahead of print. Lancet Infect Dis. 2024. PMID: 39389071
Integration of individual preclinical and clinical anti-infective PKPD data to predict clinical study outcomes.
Aranzana-Climent V, van Os W, Nutman A, Lellouche J, Dishon-Benattar Y, Rakovitsky N, Daikos GL, Skiada A, Pavleas I, Durante-Mangoni E, Theuretzbacher U, Paul M, Carmeli Y, Friberg LE. Aranzana-Climent V, et al. Among authors: carmeli y. Clin Transl Sci. 2024 Jul;17(7):e13870. doi: 10.1111/cts.13870. Clin Transl Sci. 2024. PMID: 38952168 Free PMC article. Clinical Trial.
419 results